narmac - I am not expecting the start of any new trials with this financing. It could defiantly happen but finishing BoM is still top priority. This will get them to the end of the trial and not just to Top Line results. The loan is due in May so it will be close as to whether the full data is ready by then. Having all patients continuing in the trial until all 250 events happen added costs to the trial as well. This is very welcome news this morning.

This placement makes sense to put shares in the hands of the market makers on the south side of the boarder prior to a US listing. Kind of like greasing the wheels before you get the machine going.

All IMO

tada